Therapeutic Indications

Budesonide is indicated for:

Bronchial asthma

Irrespective of gender only Children (1 year - 12 years old)

Treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Respiratory (Inhalation) - 0.5-1 mg in 2 divided doses daily

Seasonal and perennial allergic rhinitis

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

Treatment and prevention of signs and symptoms of seasonal and perennial allergic rhinitis.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Respiratory (Inhalation) - 256 mcg in 2 doses daily

Nasal polyps

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

Treatment of signs and symptoms of nasal polyps.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Respiratory (Inhalation) - 256 mcg once daily

Psoriasis, lichen lichen, licorice lichen, palladium and phalctinosis

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Cutaneous - 2 actuations daily

Chronic obstructive pulmonary disease

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Respiratory (Inhalation) - 0.5-2 mg in 2 divided doses daily

Collagenous colitis

Irrespective of gender only Adults (18 years old or older)

Induction of remission in patients with active collagenous colitis.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 9mg once daily in the morning

Crohn's disease

Irrespective of gender only Adults (18 years old or older)

Induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum and/or the ascending colon.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 9mg once daily in the morning

Autoimmune hepatitis

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 9mg in three divided doses

Ulcerative colitis

Irrespective of gender only Adults (18 years old or older)

For the treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Rectal - 2mg once daily

Pseudocroup (laryngitis subglottica)

Irrespective of gender only Infants (40 days - 1 year old) , Children (1 year - 12 years old)

Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Respiratory (Inhalation) - 2 mg in a single administration

Bronchial asthma

Irrespective of gender only Adolescents (12 years - 18 years old) Adults (18 years old or older)

Treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Respiratory (Inhalation) - 0.5-2 mg in 2 divided doses daily

Contraindications

Active ingredient Budesonide is contraindicated in the following cases:

Cirrhosis of liver

No gender/age discrimination